Compare Hikma Pharmaceuticals Plc with Similar Stocks
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-14.92%
0%
-14.92%
6 Months
-22.26%
0%
-22.26%
1 Year
-31.97%
0%
-31.97%
2 Years
-19.24%
0%
-19.24%
3 Years
-9.01%
0%
-9.01%
4 Years
-25.32%
0%
-25.32%
5 Years
-35.35%
0%
-35.35%
Hikma Pharmaceuticals Plc for the last several years.
Risk Adjusted Returns v/s 
News

Hikma Pharmaceuticals Hits Day Low of GBP 15.22 Amid Price Pressure
Hikma Pharmaceuticals Plc has faced notable stock volatility, hitting an intraday low and experiencing significant declines over various timeframes. Despite maintaining high management efficiency and a low debt-to-equity ratio, the company is challenged by rising raw material costs and a substantial drop in pre-tax profit.
Read full news article Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
6.43%
EBIT Growth (5y)
-3.24%
EBIT to Interest (avg)
7.98
Debt to EBITDA (avg)
1.03
Net Debt to Equity (avg)
0.45
Sales to Capital Employed (avg)
0.81
Tax Ratio
20.49%
Dividend Payout Ratio
48.77%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
18.66%
ROE (avg)
16.01%
Valuation key factors
Factor
Value
P/E Ratio
16
Industry P/E
Price to Book Value
2.15
EV to EBIT
12.85
EV to EBITDA
9.05
EV to Capital Employed
1.77
EV to Sales
1.98
PEG Ratio
10.85
Dividend Yield
1.11%
ROCE (Latest)
13.74%
ROE (Latest)
13.78%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot : Jun 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
2,312.90
2,043.40
13.19%
Operating Profit (PBDIT) excl Other Income
548.60
565.00
-2.90%
Interest
70.00
56.80
23.24%
Exceptional Items
-98.10
-157.50
37.71%
Consolidate Net Profit
154.50
155.10
-0.39%
Operating Profit Margin (Excl OI)
170.80%
201.00%
-3.02%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is 13.19% vs 10.08% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is -0.39% vs -49.21% in Dec 2022
About Hikma Pharmaceuticals Plc 
Hikma Pharmaceuticals Plc
Pharmaceuticals & Biotechnology
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company's segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets. The Company sells specialized generic injectable products across the globe. It also sells non-injectable generic products in the United States, supplying over 300 products in different dosage strengths and forms. The Company's other businesses comprise Arab Medical Containers, a manufacturer of plastic specialized medicinal sterile containers, International Pharmaceuticals Research Centre, which conducts bio-equivalency studies, and the active pharmaceutical ingredient (API) manufacturing division of Hikma Pharmaceuticals Limited Jordan.
Company Coordinates 
Company Details
1 New Burlington Place , LONDON None : W1S 2HR
Registrar Details






